ADVERTISEMENT
Dr Shah Discusses HER-RAM Study Results in HER2+ GI Cancers
06/15/2021
Manish Shah, MD, highlights the multi-center, phase 1b/2 study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study), presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement